































Flame  aerosol  technology  is  a  versatile  method  for  scalable 
synthesis  of  nanoparticles.  Since  particles  are  produced  and 
collected in a dry state, dispersibility and further functionalization 
could pose hurdles  to  their biomedical use. We  report on a one‐
pot,  scalable  and  robust procedure  for  the  PEGylation of  flame‐




Flame aerosol technology is a versatile process that allows large 
scale production of high quality nanoparticles.1, 2 Its broad use for 
decades further evidences the process robustness and applicability 
for synthesis of nanoparticles, even by industrial standards.3 Spray 
combustion of solutions4 has been employed for preparing a wide 
range of mono- and multicomponent nanoparticles at low cost and 
with high yields in commercial quantities.5 It can be scaled up to a 
production rate of kg per hour6 without significant alterations in 
material characteristics,7 and specifically for biomedically relevant 
materials.8, 9 In the recent years, flame-made particles with diverse 
compositions and architectures (including core/shell10 and Janus 
shaped11, 12 particles) have attracted increasing interest in the 
biomedical field. The good stoichiometric control and scalability of 
the process along with the sterility of the high temperature 
conditions make flame spray pyrolysis4 an attractive method for 
synthesis13 of nanoparticles for diagnostic9 and therapeutic use.14 
While some applications are based on the incorporation of flame-
made nanoparticles into polymeric matrices and composites,15, 16 
others rely on direct topical application of nanoparticles without any 
functionalization.17 However, such fumed metal oxide nanoparticles 
can be damaging to cells.18, 19 Especially flame-made silica and 
silica-rich materials have been shown to activate blood coagulation 
and lyse cellular membranes.20, 21 
While surface modification of such nanoparticles can effectively 
attenuate the damaging effects,22 stabilization and further 
functionalization of flame-made particles often is challenging. 
Among the different strategies available to modify the surface of 
nanoparticles, functionalization with poly(ethylene glycol) chains 
(PEGylation) is first choice, primarily because the hydrophilic and 
flexible PEG chains disperse well in physiological media due to 
steric repulsion.23 Additionally, it has been shown that surface 
PEGylation attenuates non-specific protein adsorption,24 prolongs 
blood circulation times and reduces uptake into phagocytic cells.22 
While it is relatively straightforward to achieve high surface grafting 
densities with small molecules (such as silanes),25 it generally 
remains challenging to achieve high PEG-chain grafting densities on 
the nanoparticle surface. A promising method for in situ 
functionalization of flame-made titania nanoparticles with 
hydrophobic moieties that were thermally stable up to 300°C in air 
was reported,26 however, its applicability for PEG-based silanes has 
yet to be demonstrated. Various strategies have been developed for 
PEGylation of metal oxide nanoparticles.27 Most of them involve the 
use of PEG derivatives with reactive chain ends (such as silanes28 
and phosphonates29-31) or sophisticated surface polymerization 
reactions of PEG-like monomers. Other methods include Atom 
Transfer Radical Polymerization (ATRP)32 and reversible addition-
fragmentation chain transfer (RAFT)-based approaches.33 However, 
there is a need for more straightforward, user-friendly and 
universally applicable alternatives not relying on expert know-how 
or expensive reactive-group terminated PEG moieties. 
Melt grafting was developed in the 1980s as a straightforward route 
for the hydrophobization of sol-gel (Stöber) silica particles. In the 
original protocols, silica particles dispersed in a long-chain alcohol 
(such as stearyl alcohol) were heated to 180-200 °C (usually for 1 to 
3 hrs) to promote the esterification reaction between the surface 
silanols and the alcohol -OH groups, through the formation of Si–O–





polar organic solvents.35 However, interest for this approach was lost 
when hydrophobic silanes started to become widely available.36 
More recently, melt-grafting protocols started again to attract 
attention due to their simplicity. For example, an approach for 
meltPEGylation of iron oxide particles has been recently reported,23 
which however, makes use of particles first functionalized with 
nitrodopamine or nitrodopamine-PEG chains and thus does not 
constitute a one-pot approach analogous to the historical method.  
Here, we present an effective, robust and straightforward route to 
obtain stabilized colloids of flame-made nanoparticles using low cost 
monomethylether-terminated PEG. We demonstrate the versatility of 
the meltPEGylation protocol by applying it to two different oxide 
nanoparticles, luminescent terbium-doped yttria (Y2O3:Tb3+) and 
silica (SiO2). Luminescent Y2O3:Tb3+ nanoparticles were included as 
a biomedically-promising material with prospective applications in 
labelling of cancerous cells.37 Flame-made SiO2 is a commercially 
relevant and well-known material with comparatively poor cyto-15 
and hemocompatibility.17, 21 In addition, silica has been historically 
important in the development of melt-grafting protocols,34 and is 
thus used for benchmarking. The obtained PEG grafting densities are 
compared to those achieved by simple PEG physisorption and PEG-
silane grafting. To assess the feasibility of meltPEGylated flame-
made metal oxide nanoparticles for biomedical applications, their 
properties such as colloidal stability over time, cytocompatibility, 
activation of the blood coagulation cascade and uptake into 
phagocytes were investigated.  
Both Y2O3:Tb3+ and SiO2 nanoparticles were prepared by flame 
spray pyrolysis following previously reported protocols.21, 38 In brief, 
metal organic precursor solutions, containing the desired 
stoichiometric amounts of elements, were prepared and combusted. 
Particles were collected on a filter downstream of the flame and 
subsequently subjected to physicochemical characterization. The 
specific surface area measured by N2 adsorption (BET method) was 
230 m2/g for silica and 71 m2/g for Tb3+-doped yttria nanoparticles. 
The corresponding average primary particle sizes (dBET) were 10 nm 
for SiO2 and 16 nm for Y2O3:Tb3+, in line with values reported in 
literature obtained under comparable process conditions.21, 38 
Nanoparticle morphology was studied by transmission electron 
microscopy (TEM) and crystallinity by X-ray powder diffraction 
(XRD) (Figures 1a,b and S1). Y2O3:Tb3+ nanoparticles are 
monoclinic and highly crystalline, while silica is amorphous, which 
is in good agreement with the literature.21,31 The carbon content of 
as-prepared nanoparticles prior to surface modification determined 
by elemental analysis (CHN analysis) was < 0.1 wt%. The as-
prepared materials were then subjected to two different PEGylation 
protocols, namely meltPEGylation and PEG physisorption. For 
meltPEGylation, a procedure similar to the historical method was 
used.34 In short, as-prepared nanoparticles were ground in a mortar 
together with poly(ethylene glycol) monomethyl ether. PEG 
monomethyl ether was chosen to avoid cross-linking. After mixing 
with ethanol and subsequent solvent evaporation, the solid was 
heated to 200 °C under inert atmosphere and nanoparticles were 
washed repeatedly with solvents (see ESI for detailed methods). For 
the PEG physisorption protocol, the nanoparticles were directly 
dispersed in solvents containing dissolved PEG and washed 
afterwards. The grafting densities calculated from the PEG loading 
and the BET surface were distinct for the different functionalization 
routes (Table 1: CHN analysis). The highest grafting densities (1.2 
chains per nm2 for Y2O3:Tb3+ and 0.8 chains per nm2 for SiO2) were 
found for particles functionalized by the meltPEGylation route using 
PEG350. For Y2O3:Tb3+, a 50% increase in PEG loading using 
meltPEGylation compared to physisorption was found for all three 
molecular weights studied (350, 1900 and 5000 Da). For 
comparison, surface grafting densities for functionalization with 
commercially available PEG-silanes following the protocol 
described by Lucky et al.39 were included in Table 1. Grafting 
densities obtained by the meltPEGylation route are comparable to 
reported maximum PEG densities on silica (0.24-2.3 chains per 
nm2)40 and iron oxide (0.5-3 chains per nm2).  23 Importantly, 
meltPEGylation can give access to a brush-like conformation of 
PEG. The average distance D between neighboring PEG chains on 
particle surface determines the structural conformation of the 
surface-attached PEG chains and thus its shielding effectiveness. If 
D is greater than the Flory radius RF, that, is, if RF/D ≤ 1, 
neighboring PEG chains will not overlap and are said to be in a 
“mushroom” conformational regime. However, as the surface PEG 
density increases such that adjacent PEG chains overlap, that is, if 
RF/D > 1, PEG chains are forced to stretch away from the particle 
surface forming a “brush” layer. It is generally believed that surface 
Figure 1: Transmission electron micrographs  (TEM) of SiO2  (a) and Y2O3:Tb3+  (b). 
Dynamic  light scattering  (DLS) measurements  for Y2O3:Tb3+ and SiO2 nanoparticle 









PEG densities in the mushroom-to-brush transition state are required 
to offer optimal performance.41 The results obtained for Y2O3:Tb3+ 
suggest that while PEG physisorption leads only to a “mushroom” 
state, meltPEGylation can give access to a “brush” layer (ESI, Table 
S1). Densities are likely to vary between different particles due to 
different compositions and availabilities of surface hydroxyl groups.  
The phase and the luminescent properties of the Y2O3:Tb3+ particles 
remained unaltered after PEGylation (ESI, Figure S1 and S2). 
Fourier transform infrared spectroscopy further confirmed the 
presence of PEG on both Y2O3:Tb3+ and SiO2 nanoparticles (ESI, 
Figure S1). X-ray photoelectron spectroscopy of meltPEG on silica 
showed a small chemical shift towards Si-O-C, however, the Si-O-C 
and O-Si-O peak show significant overlap (ESI, Figure S2). 
Following PEGylation, colloidal size and particle sedimentation 
were measured by DLS and ultraviolet-visible (UV-Vis) 
spectroscopy using particle suspensions in water and cell culture 
medium (Figures 1b and S3 (ESI)). From DLS measurements in 
water, it became evident that meltPEGylated yttria nanoparticles 
have smaller hydrodynamic diameters compared to non-
functionalized and physisorbed PEG nanoparticles (Figure 1c). 
Particles with the shortest polymer chain length (i.e. 350 Da) have 
the smallest hydrodynamic size (ESI, Figure S3a) and the highest 
grafting densities. Therefore, nanoparticles functionalized with 
PEG350 were selected for further investigations. The polydispersity 
indices (PDI) (see Figure S3a) were generally smaller for 
meltPEGylated particles compared to the values observed for 
physisorbed PEG particles. In cell culture medium, meltPEGylated 
Y2O3:Tb3+ nanoparticles remained much smaller compared to 
physisorbed PEG nanoparticles (see ESI Figure S3 b-f for raw 
data). While hydrodynamic sizes of PEGylated silica nanoparticles 
were significantly larger in cell culture medium compared to water, 
non-functionalized silica nanoparticles remained remarkably small in 
serum-containing medium. This is in agreement with previous 
reports showing high stability of non-functionalized silica at similar 
concentrations in cell culture medium over time.42 . Interestingly, 
when dispersions were measured immediately after preparation, 
hydrodynamic sizes were comparable for all nanoparticles (in both 
water and medium) and below 300 nm (see ESI, Figure S4). The 
differences in long-term stability indicate that the PEG chain length 
and purification protocols may require optimization for different 
metal oxides and environments (buffers, protein-rich solutions, etc). 
To further characterize the colloidal stability of the Y2O3:Tb3+ 
suspensions, sedimentation over time was measured according to 
procedures described by Spyrogianni et al.42 Sedimentation was 
monitored in a 3 mm deep suspension layer over 8 hrs by UV-Vis 
spectroscopy (Figure 1d). Non-functionalized Y2O3:Tb3+ 
nanoparticles show fast sedimentation within the first 30 minutes, 
similar to those functionalized by the physisorption route. For non-
functionalized and physisorbed PEG, the dispersion reached < 5% of 
its initial absorbance after 2 hours, whereas for particles prepared by 
the meltPEGylation route, the absorbance was still > 50% of the 
initial value after 2 hrs. The sedimentation kinetics illustrates the 
improved colloidal stability of meltPEGylated particles compared to 
non-functionalized nanoparticles and those functionalized with PEG 
physisorption.  
Next, we assessed the influence of the different PEGylation routes 
on the biological fate of the nanoparticles. Cytocompatibility was 
assessed in a membrane integrity assay in a dose-dependent manner 
on human THP-1 monocytes. Since particle size is an important 
factor in cytotoxicity studies,43 that determines also particle settling 
rate,20 a suspension culture was chosen, accounting for potentially 
different sedimentation properties. Lactate dehydrogenase (LDH) 
release, as a surrogate marker for membrane damage, was studied in 
monocytes (in suspension) for Y2O3:Tb3+ and SiO2 nanoparticles in 
Figure 2: Particle  induced  lactate dehydrogenase  (LDH)  release  in THP‐1 monocytes after exposure  to non‐functionalized, physisorbed PEG and meltPEGylated yttria and silica 









serum-containing conditions (Figure 2a). Generally, silica 
nanoparticles led to higher LDH release at equivalent doses 
compared to Y2O3:Tb3+. All yttria nanoparticles displayed low 
toxicity before and after functionalization, while silica exhibited 
relevant membrane damage potential. Silica particles functionalized 
with physisorbed PEG showed cytotoxicity similar to as-prepared 
nanoparticles, whereas cells exposed to meltPEGylated silica 
nanoparticles led to significantly lower LDH release.  
To investigate whether higher PEG chain density and therefore 
reduced protein interaction could also translate into altered uptake 
into phagocytic cells, we assessed the uptake into human monocytes 
as a function of time (Figure 2b). By means of flow cytometry,44, 45 
we compared the fraction of cells associated with (i.e. membrane-
bound or uptaken) particles for Y2O3:Tb3+ nanoparticles 
functionalized with physisorbed PEG and by meltPEGylation. Cell-
free controls were measured to exclude interference from particle 
aggregates. Time-dependent shifts in the side-scattering (SSC) signal 
indicated a more rapid association and internalization of particles 
carrying physisorbed PEG compared to meltPEGylated Y2O3:Tb3+. 
These results were also confirmed for nanoparticles functionalized 
with 5000 Da PEG chains. The lower association of nanoparticles 
with cells was further verified by transmission electron microscopy 
(Figure 2c). Transmission electron micrographs were recorded for 
cell samples incubated with the different nanoparticles for 2 hours. 
For non-functionalized and physisorbed PEG samples, a higher 
number of intracellular particle agglomerates can be found compared 
to meltPEGylated samples. In meltPEGylated samples, very few 
particles are localized intracellularly. A few particle agglomerates 
associated with the outer cell membrane can be observed, indicating 
a delayed particle uptake compared to the non-functionalized and 
physisorbed PEG samples. The flow cytometry data (Figure 2b) 
together with the transmission electron micrographs (Figure 2c) 
suggest a delayed particle uptake into monocytes for meltPEGylated 
particles, which may translate into altered biodistribution. 
Hydrodynamic particle size (dH) and the stealth properties of the 
PEG are main parameters governing particle uptake kinetics, 
especially into the liver (dH > 100 nm) and spleen (dH > 200 nm).46 
If nanoparticles are intended for intravascular application, 
hemocompatibility is of utmost importance. We therefore assessed 
the effect of as-prepared and PEGylated nanoparticles on red blood 
cells (particle concentration of 0.1 mg mL-1) in a hemolysis assay 
(Figure 2d). As-prepared silica nanoparticles were highly hemolytic 
with hemolysis reaching levels > 50% relative to positive control, 
similar to commercially available fumed silica (Aerosil200). The 
high hemolytic activity of flame made and fumed silica is in good 
agreement with previous studies reporting hemolytic properties for 
different silicas,47 including Aerosil300.48 Surface PEGylation 
significantly decreased the hemolytic activity (Spearman’s rho: -
0.95, p < 0.001 (two-tailed)). This effect was most pronounced for 
meltPEG350, where hemolysis was comparable to untreated control 
(< 5%). Compared to silica, Y2O3:Tb3+ was significantly less 
hemolytic, and again the hemolytic potential was diminished as a 
function of PEG grafting density (Spearman’s rho: -0.94, p < 0.001 
(two-tailed)). Apart from hemolysis, the activation of the blood 
coagulation cascade is one of the most critical issues related to 
intravascular application. It is well known that metal oxides, and 
particularly silica nanoparticles, promote plasma coagulation.49 
Indeed, non-functionalized silica led to a significant activation of the 
plasma coagulation cascade (Figure 2e), in good agreement with 
previous reports.17, 50 Non-functionalized yttria was much less 
procoagulant in comparison to silica but still led to slightly increased 
fibrin polymerization compared to negative control. Importantly, 
both meltPEGylated Y2O3:Tb3+ and SiO2 nanoparticles showed 
attenuation of the procoagulant effect observed for non-
functionalized nanoparticles. For meltPEGylated Y2O3:Tb3+, values 
were even in the range of the negative control.  
The study demonstrates, for the first time to our knowledge, direct 
melt-grafting of readily available, monomethoxy-terminated PEG on 
a metal oxide other than silica. The results illustrate the potential of 
solvent-free meltPEGylation as an elegant (one-pot), robust and 
straightforward route to achieve high PEG grafting density on flame 
made yttria and silica nanoparticles. MeltPEGylation significantly 
improves colloidal stability, reduces procoagulant activity and 
uptake by phagocytic cells, and hence facilitates biomedical use of 
flame-made nanopowders.  
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